NHI PE Ratio & Valuation,Is NHI Overvalued

NHI Relative Valuation

NHI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NHI is overvalued; if below, it's undervalued.

Historical Valuation

National Health Investors Inc (NHI) is now in the Fair zone, suggesting that its current forward PE ratio of 23.04 is considered Fairly compared with the five-year average of 21.03. The fair price of National Health Investors Inc (NHI) is between 66.07 to 82.47 according to relative valuation methord.

Relative Value

Fair Zone

66.07-82.47

Current Price：76.77

Fair

23.04

15.35

EV/EBITDA

National Health Investors Inc. (NHI) has a current EV/EBITDA of 15.35. The 5-year average EV/EBITDA is 15.30. The thresholds are as follows: Strongly Undervalued below 12.65, Undervalued between 12.65 and 13.98, Fairly Valued between 16.63 and 13.98, Overvalued between 16.63 and 17.96, and Strongly Overvalued above 17.96. The current Forward EV/EBITDA of 15.35 falls within the Historic Trend Line -Fairly Valued range.

21.68

EV/EBIT

National Health Investors Inc. (NHI) has a current EV/EBIT of 21.68. The 5-year average EV/EBIT is 21.66. The thresholds are as follows: Strongly Undervalued below 15.89, Undervalued between 15.89 and 18.77, Fairly Valued between 24.54 and 18.77, Overvalued between 24.54 and 27.42, and Strongly Overvalued above 27.42. The current Forward EV/EBIT of 21.68 falls within the Historic Trend Line -Fairly Valued range.

9.59

National Health Investors Inc. (NHI) has a current PS of 9.59. The 5-year average PS is 8.90. The thresholds are as follows: Strongly Undervalued below 6.46, Undervalued between 6.46 and 7.68, Fairly Valued between 10.12 and 7.68, Overvalued between 10.12 and 11.34, and Strongly Overvalued above 11.34. The current Forward PS of 9.59 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

National Health Investors Inc. (NHI) has a current P/OCF of 0.00. The 5-year average P/OCF is 4.06. The thresholds are as follows: Strongly Undervalued below -6.29, Undervalued between -6.29 and -1.11, Fairly Valued between 9.23 and -1.11, Overvalued between 9.23 and 14.40, and Strongly Overvalued above 14.40. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

National Health Investors Inc. (NHI) has a current P/FCF of 0.00. The 5-year average P/FCF is 1.87. The thresholds are as follows: Strongly Undervalued below -6.07, Undervalued between -6.07 and -2.10, Fairly Valued between 5.84 and -2.10, Overvalued between 5.84 and 9.80, and Strongly Overvalued above 9.80. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

National Health Investors Inc (NHI) has a current Price-to-Book (P/B) ratio of 2.47. Compared to its 3-year average P/B ratio of 2.20 , the current P/B ratio is approximately 12.14% higher. Relative to its 5-year average P/B ratio of 2.07, the current P/B ratio is about 19.21% higher. National Health Investors Inc (NHI) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 6.79%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 7.14% , the current FCF yield is about -100.00% lower.

2.47

P/B

Median3y

2.20

Median5y

2.07

5.98

FCF Yield

Median3y

6.79

Median5y

7.14

Competitors Valuation Multiple

The average P/S ratio for NHI's competitors is , providing a benchmark for relative valuation. National Health Investors Inc Corp (NHI) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 8.32%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NHI increased by 13.61% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 82.94M to 89.85M.

The secondary factor is the Margin Expansion, contributed 6.17%to the performance.

Overall, the performance of NHI in the past 1 year is driven by Revenue Growth. Which is more sustainable.

8.32%

82.94M → 89.85M

Revenue Growth

6.17%

34.05 → 36.15

Margin Expansion

-0.88%

24.44 → 24.23

P/E Change

13.61%

67.57 → 76.77

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is National Health Investors Inc (NHI) currently overvalued or undervalued?

What is National Health Investors Inc (NHI) fair value?

NHI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of National Health Investors Inc (NHI) is between 66.07 to 82.47 according to relative valuation methord.

How does NHI's valuation metrics compare to the industry average?

What is the current P/B ratio for National Health Investors Inc (NHI) as of Dec 17 2025?

As of Dec 17 2025, National Health Investors Inc (NHI) has a P/B ratio of 2.47. This indicates that the market values NHI at 2.47 times its book value.

What is the current FCF Yield for National Health Investors Inc (NHI) as of Dec 17 2025?

As of Dec 17 2025, National Health Investors Inc (NHI) has a FCF Yield of 0.00%. This means that for every dollar of National Health Investors Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for National Health Investors Inc (NHI) as of Dec 17 2025?

As of Dec 17 2025, National Health Investors Inc (NHI) has a Forward P/E ratio of 23.04. This means the market is willing to pay $23.04 for every dollar of National Health Investors Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for National Health Investors Inc (NHI) as of Dec 17 2025?

As of Dec 17 2025, National Health Investors Inc (NHI) has a Forward P/S ratio of 0.00. This means the market is valuing NHI at $0.00 for every dollar of expected revenue over the next 12 months.

NHI Valuation